Therapeutic Misconception in Early-Phase Oncology Trials: Ethical Implications

Abstract

Patients enrolling in phase I oncology trials frequently report expecting personal therapeutic benefit from a study designed primarily to establish safe dosing, a gap between trial design and participant belief that bioethicists call the therapeutic misconception.
This commentary examines how the misconception has been defined and distinguished from adjacent constructs such as therapeutic misestimation and dispositional optimism, and why three decades of consent-form reform have produced only modest gains in participant understanding. It then considers how the rise of targeted agents, immunotherapy, and biomarker-selected enrollment has
measurably improved response rates in early-phase trials, complicating the assumption that any expressed hope of benefit reflects confusion rather than an accurate read of improved prospects. We argue that responsibility for managing the misconception cannot rest on consent documents alone, since much of the relevant communication happens in the physician-researcher relationship and is shaped by thescarcity of alternatives facing patients with treatment-refractory cancer. We conclude that consent processes calibrated to agent-specific evidence, combined with communication  training addressing how trials are described in conversation, offer a more defensible path forward than continued reliance on document revision alone.